CD177 and breast carcinoma: Interestingly, despite its normally restricted expression, elevated AGR3 levels have been observed in estrogen receptor-positive breast cancers, both within cells and in secreted forms [147,150,175,176], raising the possibility that AGR3 acts as an ER foldase for cell surface receptors, analogous to AGR2.